journal article
Sep 01, 1997
Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action
Topics
No keywords indexed for this article. Browse by subject →
References
94
[1]
Ross, C., Hansen, M.B., Schyberg, T. and Berg, K. 1990. Autoantibodies to crude human leukocyte interferon (IFN), native human IFN-β, recombinant human IFN-α 2b and human IFN-γ in healthy blood donors. Clin. exp. Immunol.82: 57–62.
10.1111/j.1365-2249.1990.tb05403.x
[2]
Mogensen, K.E., Daubas, P.H., Gresser, I., Sereni, D. and Varet, B. 1981. Patient with circulating antibodies toα-interferon. LancetII, 1227–1228.
10.1016/s0140-6736(81)91460-4
[3]
Bendtzen, K., Hansen, M.B., Diamant, M., Ross, C. and Svenson, M. 1994. Naturally occurring autoantibodies to interleukin-1α, interleukin-6, interleukin-10 and interferon-α. J. Interferon Res.14: 157–158.
10.1089/jir.1994.14.157
[4]
Svenson, M., Poulson, L.K., Fomsgaard, A. and Bendtzen, K. 1989. IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand. J. Immunol.29: 489–492.
10.1111/j.1365-3083.1989.tb01149.x
[5]
Tiberio, L., Caruso, A., Pozzi, A., Rivoltini, L., Morelli, D., Monti, E. and Balsari, A. 1993. The detection and biological activity of human antibodies to IL-2 in normal donors. Scand. J. Immunol.38: 472–476.
10.1111/j.1365-3083.1993.tb02590.x
[6]
Hansen, M.B., Svenson, M., Diamant, M. and Bendtzen, K. 1991. Anti-interleukin-6 antibodies in normal human serum. Scand. J. Immunol.33: 777–781.
10.1111/j.1365-3083.1991.tb02552.x
[7]
Takemura, H., Suzuki, H., Yoshizaki, K., Ogata, A., Yuhara, T., Akama, T., Yamane, K. and Kashiwagi, H. 1992. Anti-interleukin-6 autoantibodies in rheumatic diseases: increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum.35: 940–943.
10.1002/art.1780350814
[8]
Menetrier-Caux, C., Briere, F., Jouvenne, P., Peyron, E., Peyron, F. and Banchereau, J. 1996. Identification of human IgG autoantibodies specific for IL-10. Clin. Exp. Immunol.104: 173–179.
10.1046/j.1365-2249.1996.d01-646.x
[9]
Hoffman, R., Briddle, R.A., Van Besien, K., Srour, E.F., Guscar, T., Hudson, N.W. and Ganser, A. 1989. Acquired cyclic amegakaryocytic thrombocytopenia associated with an immunoglobulin blocking the action of granulocytemacrophage colony- stimulating factor. N. Engl. J. Med.321: 97–102.
10.1056/nejm198907133210207
[10]
Fomsgaard, A., Svenson, M. and Bendtzen, K. 1989. Autoantibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and Gram-negative bacterial infections. Scand. J. Immunol.30: 219–223.
10.1111/j.1365-3083.1989.tb01204.x
[11]
Suzuki, H., Takemura, H., Yoshizaki, K., Koishihara, Y., Ohsugi, Y., Okano, A., Akiyama, Y., Tojo, T., Kishimoto, T. and Kashiwagi, H. 1994. IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J. Immunol.152: 935–942.
10.4049/jimmunol.152.2.935
[12]
De Maeyer-Guignard, J., Cachard-Thomas, A. and De Maeyer, E., 1984. Naturally occurring anti-interferon antibodies in Lou/c rats. J. Immunol.133: 775–779.
10.4049/jimmunol.133.2.775
[13]
De Maeyer-Guignard, J. and De Maeyer, E. 1986. Natural antibodies to interferon alpha and interferon beta are a common feature of inbred mouse strains. J. Immunol.136: 1708–1712.
10.4049/jimmunol.136.5.1708
[14]
Bendtzen, K., Svenson, M., Jønsson, V. and Hippe, E. 1990. Autoantibodies to cytokines: friends or foes. Immunol. Today11: 167–169.
10.1016/0167-5699(90)90068-k
[15]
Pozzetto, B., Mogensen, K.E., Tovey, M.G. and Gresser, I. 1984. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J. Infect. Dis.150: 707–713.
10.1093/infdis/150.5.707
[16]
Ross, C., Svenson, M., Hansen, M.B., Veijlsgaard, G.L. and Bendtzen, K. 1994. Specific autoantibodies directed against interferon-alpha in pharmaceutically prepared human immunoglobulin preparations. J. Interferon Res.14: 159–160.
10.1089/jir.1994.14.159
[17]
Caruso, A., Bonfanti, C., Colombrita, D., De Francesco, M., De Rango, C., Foresti, I., Gargiulo, F., Gonzales, R., Gribaudo, G., Landolfo, S., Manca, N., Manni, M., Pirali, F., Pollara, P., Ravizzola, G., Scura, G., Terlenghi, L., Viani, E. and Turano, A. 1990. Natural antibodies to IFN-gamma in man and their increase during viral infection. J. Immunol.144: 685–690.
10.4049/jimmunol.144.2.685
[18]
Caruso, A., Foresti, G., Gribaudo, G., Bonfanti, C., Pollara, P., Dolei, A., Landolfo, S. and Turano, A. 1989. Anti-interferon-γ antibodies in sera from HIV-infected patients. J. Biol. Homeost. Agents3: 8–12.
[19]
Bonfanti, C., Caruso, A., Bakhiet, M., Olsson, T., Turano, A. and Kristensson, K. 1994. Increased levels of antibodies to IFN-γ in human and experimental african trypanosomiasis. Scand. J. Immunol.41: 49–52.
10.1111/j.1365-3083.1995.tb03532.x
[20]
Salahuddin, S.Z., Markham, P.D., Lindner, S.G., Gootenberg, J., Popovic, M., Hemmi, H., Sarin, P.S. and Gallo, R.C. 1984. Lymphokine production by cultured human T cells transformed by human T cell leukemia-lymphoma virus-1. Science223: 703–707.
10.1126/science.6320367
[21]
Van der Meide, P.H., Groenestein, R.J., De Labie, M.C.D.C., Heeney, J., Pala, P. and Slaoui, M. 1995. Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. J. Med. Primatol.24: 271–281.
10.1111/j.1600-0684.1995.tb00181.x
[22]
Bakhiet, M., Olsson, T., Mhlanga, J., Büscher, P., Lycke, N., Van der Meide, P.H. and Kristensson, K. 1996. Human and rodent interferon-γ as a growth factor for trypanosoma brucei. Eur. J. Immunol.26: 1359–1364.
10.1002/eji.1830260627
[23]
Panem, S., Check, I.J., Henriksen, D. and Vilçek, J. 1982. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J. Immunol.129: 1–3.
10.4049/jimmunol.129.1.1
[24]
Nolte, K.U., Jakschies, D., Pestka, S. and Von Wussow, P. 1994. Different specificities of SLE-derived and therapy-induced interferon-alpha antibodies. J. Interferon Res.14: 197–199.
10.1089/jir.1994.14.197
[25]
Shou-Nee, S., Shu Fang, F., Yumei, W., Li Fang, H. and Yao Xing, H. 1987. Serum interferon in systemic lupus erythematosus. Br. J. Dermatol.117: 155–159.
10.1111/j.1365-2133.1987.tb04111.x
[26]
Preble, O.T., Black, R.J., Friedman, R.M., Klippel, J.H. and Vilçek, J. 1982. Systemic lupus erythematosus: presence in humans of unusual acid-labile leukocyte interferon. Science216: 429–431.
10.1126/science.6176024
[27]
Ytterberg, S.R. and Schnitzer, T.J. 1982. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum.25: 401–406.
10.1002/art.1780250407
[28]
Cesario, T.C., Andrews, B.S., Martin, D.A., Jason, M., Treadwell, T., Friou, G. and Tilles, J.G. 1983. Interferon in synovial fluid and serum of patients with rheumatic diseases. J. Rheumatol.10: 647–650.
[29]
Arvin, A.M. and Miller, J.J. III. 1984. Acid labile α-interferon in sera and synovial fluids from patients with juvenile arthritis. Arthritis Rheum.27: 582–585.
10.1002/art.1780270517
[30]
Prümmer, O., Seyfarth, C., Scherbaum, W.A., Drees, N., and Porzsolt, F. 1989. Interferon-α antibodies in autoimmune disease. J. Interferon Res.9, suppl. 1, S67-S74.
[31]
Rönnblom, L.E., Alm, G.V. and Oberg, K.E. 1991. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Int. Med.115: 178–183.
10.7326/0003-4819-115-3-178
[32]
Heremans, S., Billiau, A., Colombatti, A., Hilgers, J. and De Somer, P. 1978. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect. Immun.21: 925–930.
10.1128/iai.21.3.925-930.1978
[33]
Chazerain, P., Meyer, O. and Kahn, M.F. 1992. Rheumatoid arthritis-like disease after alpha interferon therapy. Ann. Intern. Med.116: 427.
10.7326/0003-4819-116-5-427_1
[34]
Adam, C., Thoua, Y.T., Ronco, P., Verroust, P., Tovey, M. and Morel-Maroger, L. 1980. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W)F1 mice. Clin. Exp. Immunol.40: 373–382.
[35]
Gresser, I., Maury, C., Tovey, M., Morel-Maroger, L. and Pontillon, F. 1976. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature263: 420–422.
10.1038/263420a0
[36]
Rosenbach, T.O., Moshonov, S., Zor, U and Yaron, M. 1984. Interferon triggers experimental synovitis and may potentiate auto-immune diseases in humans. Clin. Rheumatol.3: 361–364,
10.1007/bf02032343
[37]
Rich, S.A. 1981. Human lupus inclusions and interferon. Science213: 772–775.
10.1126/science.6166984
[38]
Belardelli, F. and Gresser, I. 1996. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today17: 369–372.
10.1016/0167-5699(96)10027-x
[39]
Skurkovich, S.V. and Eremkina, E.I. 1975. The probable role of interferon in allergy. Ann. Allergy35: 356–360.
[40]
Gresser, I., Morel-Maroger, L. and Verroust, P., Rivière, Y. and Guillon, J.-C. 1978. Anti-interferon globulin inhibits the development of glomerulonephritis in mice infected at birth with lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. U.S.A.75: 3413–3416.
10.1073/pnas.75.7.3413
[41]
Panitch, H.S. 1992. Interferons in multiple sclerosis. A review of the evidence. Drugs44: 946–962.
10.2165/00003495-199244060-00004
[42]
Weinstock-Guttman, B., Ransohoff, M., Kinkel, R.P. and Rudick, R.A. 1995. The interferons: biological effects, mechanisms of action and use in multiple sclerosis. Ann. Neurol.37: 7–15.
10.1002/ana.410370105
[43]
Stone, L.A., Frank, J.A., Albert, P.S., Bash, C., Smith, M.E., Maloni, H. and McFarland, H.F. 1995. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol.37: 611–619.
10.1002/ana.410370511
[44]
Ruuls, S.R., De Labie, M.C.D.C., Weber, K.S., Botman, C.A.D., Groenestein, R.J., Dijkstra, C.D., Olsson, T. and Van der Meide, P.H. 1996. The length of treatment determines whether IFN-β prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J. Immunol.157: 5721–5731.
10.4049/jimmunol.157.12.5721
[45]
Skurkovich, S., Skurkovich, B. and Bellanti, J.A. 1987. A unifying model of the immunoregulatory role of the interferon system: can interferon produce disease in humans? Clin. Immunol. Immunopathol.43: 362–373.
10.1016/0090-1229(87)90146-2
[46]
Schattner, A. 1988. Review: Interferons and autoimmunity. Am. J. Med. Sci.295: 532–544.
10.1097/00000441-198806000-00007
[47]
Porrini, A.M., Gambi, D. and Reder, A.T. 1995. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J. Neuroimmunol.61: 27–34.
10.1016/0165-5728(95)00070-i
[48]
Aman, M.J., Tretter, T., Eisenbeis, I., Bug, G., Decker, T., Aulitzky, W.E., Tilg, H., Huber, C. and Peschel, C. 1996. Interferon-α stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood87: 4731–4736.
10.1182/blood.v87.11.4731.bloodjournal87114731
[49]
Rousset, F., Garcia, E., Defrance, T., Peronne, C., Vezzio, N., Hsu, D.H., Kastelein, R., Moore, K.W. and Banchereau, J. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. U.S.A.89: 1890–1893.
10.1073/pnas.89.5.1890
[50]
Llorente, L., Zou, W., Levy, Y., Richaud-Patin, Y., Wijdenes, J., Alcocer-Varela, J., Morel- Fourrier, B., Brouet, J.C., Alarcon-Segovia, D., Galanaud, P. et al. 1995. Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med.181: 839–844.
10.1084/jem.181.3.839
Showing 50 of 94 references
Metrics
26
Citations
94
References
Details
- Published
- Sep 01, 1997
- Vol/Issue
- 10(1)
- Pages
- 39-48
- License
- View
Cite This Article
Peter H. van der Meide, Huub Schellekens (1997). Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action. Biotherapy, 10(1), 39-48. https://doi.org/10.1007/bf02678216
Related